Design Requirements for Interfering Particles To Maintain Coadaptive Stability with HIV-1

Journal of Virology

Volumn 87, Issue 4, 2013, Pages 2081-2093

  Rouzine, Igor M ^a   Weinberger, Leor S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DEFECTIVE INTERFERING PARTICLE; DIMERIZATION; GENE DOSAGE; GENETIC RECOMBINATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PARASITISM; PLASTICITY; PRIORITY JOURNAL; PROTEIN STABILITY; RNA SPLICING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VIRION; VIRUS CAPSID; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION;

DEFECTIVE VIRUSES; EVOLUTION, MOLECULAR; HIV-1; MODELS, THEORETICAL; RECOMBINATION, GENETIC; SELECTION, GENETIC; VIRUS REPLICATION;

EID: 84873803603     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02741-12     Document Type: Article

References (80)

1. Holland J. 1990. Generation and replication of defective viral genomes, p 77-99. In Fields BN, Knipe DM (ed), Virology. Raven Press, New York, NY.
2. Huang AS, Baltimore D. 1970. Defective viral particles and viral disease processes. Nature 226:325-327.
3. Chattopadhyay SK, Morse HC, 3rd, Makino M, Ruscetti SK, Hartley JW. 1989. Defective virus is associated with induction of murine retrovirus- induced immunodeficiency syndrome. Proc. Natl. Acad. Sci. U. S. A. 86:3862-3866.
4. Voynow SL, Coffin JM. 1985. Truncated gag-related proteins are produced by large deletion mutants of Rous sarcoma virus and form virus particles. J. Virol. 55:79-85.
5. Holland JJ, Villarreal LP. 1975. Purification of defective interfering T particles of vesicular stomatitis and rabies viruses generated in vivo in brains of newborn mice. Virology 67:438-449.
6. McLain L, Armstrong SJ, Dimmock NJ. 1988. One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J. Gen. Virol. 69:1415-1419.
7. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC. 2006. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 311:236-238.
8. Li D, Lott WB, Lowry K, Jones A, Thu HM, Aaskov J. 2011. Defective interfering viral particles in acute dengue infections. PLoS One 6:e19447. doi:10.1371/journal.pone.0019447.
9. Cook WJ, Green KA, Obar JJ, Green WR. 2003. Quantitative analysis of LP-BM5 murine leukemia retrovirus RNA using real-time RT-PCR. J. Virol. Methods 108:49-58.
10. Kubo Y, Kakimi K, Higo K, Kobayashi H, Ono T, Iwama Y, Kuribayashi K, Hiai H, Adachi A, Ishimoto A. 1996. Possible origin of murine AIDS (MAIDS) virus: conversion of an endogenous retroviral p12gag sequence to a MAIDS-inducing sequence by frameshift mutations. J. Virol. 70:6405-6409.
11. Paun A, Shaw K, Fisher S, Sammels LM, Watson MW, Beilharz MW. 2005. Quantitation of defective and ecotropic viruses during LP-BM5 infection by real time PCR and RT-PCR. J. Virol. Methods 124:57-63.
12. Barrett AD, Dimmock NJ. 1986. Defective interfering viruses and infections of animals. Curr. Top. Microbiol. Immunol. 128:55-84.
13. Cave DR, Hendrickson FM, Huang AS. 1985. Defective interfering virus particles modulate virulence. J. Virol. 55:366-373.
14. Dimmock NJ. 1985. Defective interfering viruses: modulators of infection. Microbiol. Sci. 2:1-7.
15. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 103:17372-17377.
16. Marriott AC, Dimmock NJ. 2010. Defective interfering viruses and their potential as antiviral agents. Rev. Med. Virol. 20:51-62.
17. Metzger VT, Lloyd-Smith JO, Weinberger LS. 2011. Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput. Biol. 7:e1002015. doi:10.1371/journal.pcbi.1002015.
18. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
19. Turner AM, De La Cruz J, Morris KV. 2009. Mobilization-competent lentiviral vector-mediated sustained transcriptional modulation of HIV-1 expression. Mol. Ther. 17:360-368.
20. Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S. 2009. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 83:2715-2727.
21. DePolo NJ, Holland JJ. 1986. Very rapid generation/amplification of defective interfering particles by vesicular stomatitis virus variants isolated from persistent infection. J. Gen. Virol. 67:1195-1198.
22. - mutant of vesicular stomatitis virus. J. Virol. 62:3614-3621.
23. O'Hara PJ, Horodyski FM, Nichol ST, Holland JJ. 1984. Vesicular stomatitis virus mutants resistant to defective-interfering particles accumulate stable 5=-terminal and fewer 3=-terminal mutations in a stepwise manner. J. Virol. 49:793-798.
24. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication- competent and -defective viral genomes. J. Virol. 65:3973-3985.
25. Bukovsky AA, Song JP, Naldini L. 1999. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73:7087-7092.
26. Chen CJ, Banerjea AC, Harmison GG, Haglund K, Schubert M. 1992. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20:4581-4589.
27. Evans JT, Garcia JV. 2000. Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum. Gene Ther. 11:2331-2339.
28. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
29. Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, Rosenblatt J. 2001. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol. Ther. 3:928-939.
30. Paik SY, Banerjea A, Chen CJ, Ye Z, Harmison GG, Schubert M. 1997. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis. Hum. Gene Ther. 8:1115-1124.
31. Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, Bushman FD. 2010. HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol. Ther. 18:803-811.
32. Kirkwood TB, Bangham CR. 1994. Cycles, chaos, and evolution in virus cultures: a model of defective interfering particles. Proc. Natl. Acad. Sci. U. S. A. 91:8685-8689.
33. Nelson GW, Perelson AS. 1995. Modeling defective interfering virus therapy for AIDS: conditions for DIV survival. Math. Biosci. 125:127-153.
34. Thompson KA, Yin J. 2010. Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol. J. 7:257. doi:10 .1186/1743-422X-7-257.
35. Weinberger LS, Schaffer DV, Arkin AP. 2003. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 77:10028-10036.
36. Perrault J, Holland JJ. 1972. Absence of transcriptase activity or transcription- inhibiting ability in defective interfering particles of vesicular stomatitis virus. Virology 50:150-170.
37. DePolo NJ, Giachetti C, Holland JJ. 1987. Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J. Virol. 61: 454-464.
38. Horodyski FM, Holland JJ. 1980. Viruses isolated from cells persistently infected with vesicular stomatitis virus show altered interactions with defective interfering particles. J. Virol. 36:627-631.
39. Steinhauer DA, de la Torre JC, Meier E, Holland JJ. 1989. Extreme heterogeneity in populations of vesicular stomatitis virus. J. Virol. 63: 2072-2080.
40. Batorsky R, Kearney MF, Palmer SE, Maldarelli F, Rouzine IM, Coffin JM. 2011. Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection. Proc. Natl. Acad. Sci. U. S. A. 108:5661-5666.
41. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-488.
42. Frost SD, Dumaurier MJ, Wain-Hobson S, Brown AJ. 2001. Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 98:6975-6980.
43. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J. Virol. 74:6262-6268.
44. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
45. Brown AJ. 1997. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. U. S. A. 94:1862-1865.
46. Neher RA, Leitner T. 2010. Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput. Biol. 6:e1000660. doi:10.1371 /journal.pcbi.1000660.
47. Rouzine IM, Coffin JM. 1999. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:10758-10763.
48. Rouzine IM, Coffin JM. 1999. Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. J. Virol. 73:8167-8178.
49. Rouzine IM, Rodrigo A, Coffin JM. 2001. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol. Mol. Biol. Rev. 65:151-185.
50. Rouzine IM, Weinberger L. The quantitative theory of within-host viral evolution. J. Stat. Mech. Theor. Exp, in press.
51. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ. 2004. Evidence for positive epistasis in HIV-1. Science 306:1547-1550.
52. Ganusov VV, Goonetilleke N, Liu MK, Ferrari G, Shaw GM, McMichael AJ, Borrow P, Korber BT, Perelson AS. 2011. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J. Virol. 85: 10518-10528.
53. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb JM, Petropoulos CJ, Bonhoeffer S. 2011. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat. Genet. 43:487-489.
54. Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, Cai F, Perelson AS, Gao F. 2011. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J. Virol. 85:6403-6415.
55. Nowak M, May R. 2000. Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, Oxford, UK.
56. Perelson AS, Bonhoeffer S, Mohri H, Ho DD. 1999. T cell turnover in SIV infection. Science 284:555c. doi:10.1126/science.284.5414.555a.
57. Moore MD, Fu W, Nikolaitchik O, Chen J, Ptak RG, Hu WS. 2007. Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J. Virol. 81:4002-4011.
58. Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, Coffin JM, Ni N, Lockett S, Pathak VK, Hu WS. 2009. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc. Natl. Acad. Sci. U. S. A. 106:13535-13540.
59. An DS, Morizono K, Li QX, Mao SH, Lu S, Chen IS. 1999. An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J. Virol. 73:7671-7677.
60. + T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc. Natl. Acad. Sci. U. S. A. 108:11199-11204.
61. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
62. Goudsmit J, De Ronde A, Ho DD, Perelson AS. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
63. D'Costa J, Brown H, Kundra P, Davis-Warren A, Arya S. 2001. Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation. J. Gen. Virol. 82:425-434.
64. Koldej RM, Anson DS. 2009. Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair.BMC Biotechnol. 9:86. doi:10.1186/1472-6750-9-86.
65. D'Costa J, Mansfield SG, Humeau LM. 2009. Lentiviral vectors in clinical trials: current status. Curr. Opin. Mol. Ther. 11:554-564.
66. Guedj J, Neumann AU. 2010. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J. Theor. Biol. 267:330-340.
67. Haseltine EL, Yin J, Rawlings JB. 2008. Implications of decoupling the intracellular and extracellular levels in multi-level models of virus growth. Biotechnol. Bioeng. 101:811-820.
68. Krakauer DC, Komarova NL. 2003. Levels of selection in positive-strand virus dynamics. J. Evol. Biol. 16:64-73.
69. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 271:1582-1586.
70. Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD. 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71:7518-7525.
71. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. 2007. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc. Natl. Acad. Sci. U. S. A. 104:17441-17446.
72. Ke R, Lloyd-Smith JO. 2012. Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors. PLoS Comput. Biol. 8:e1002744. doi:10.1371/journal.pcbi.1002744.
73. Paillart JC, Shehu-Xhilaga M, Marquet R, Mak J. 2004. Dimerization of retroviral RNA genomes: an inseparable pair. Nat. Rev. 2:461-472.
74. Rainey GJA, Coffin JM. 2006. Evolution of broad host range in retroviruses leads to cell death mediated by highly cytopathic variants. J. Virol. 80:562-570.
75. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77:5037-5038.
76. Rouzine IM, Sergeev RA, Glushtsov AI. 2006. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 103:666-671.
77. Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT. 2005. The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr. Biol. 15:714-723.
78. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman MA, Letvin NL. 1999. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162:5127-5133.
79. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533.
80. Sergeev RA, Batorsky RE, Rouzine IM. 2010. Model with two types of CTL regulation and experiments on CTL dynamics. J. Theor. Biol. 263: 369-384.